These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 25298108)

  • 41. Prognostic predictive values of gemcitabine sensitivity-related gene products for unresectable or recurrent biliary tract cancer treated with gemcitabine alone.
    Murata A; Amano R; Yamada N; Kimura K; Yashiro M; Nakata B; Hirakawa K
    World J Surg Oncol; 2013 May; 11():117. PubMed ID: 23710668
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Human equilibrative nucleoside transporter-1 expression is a predictor in patients with resected pancreatic cancer treated with adjuvant S-1 chemotherapy.
    Okamura Y; Yasukawa S; Narimatsu H; Boku N; Fukutomi A; Konishi M; Morinaga S; Toyama H; Kaneoka Y; Shimizu Y; Nakamori S; Sata N; Yamakita K; Takahashi A; Kainuma O; Hishinuma S; Yamaguchi R; Nagino M; Hirano S; Yanagisawa A; Mori K; Uesaka K
    Cancer Sci; 2020 Feb; 111(2):548-560. PubMed ID: 31778273
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Prognostic and predictive value of human equilibrative nucleoside transporter 1 (hENT1) in extrahepatic cholangiocarcinoma: a translational study.
    Boyd LNC; Nooijen LE; Ali M; Puik JR; Moustaquim J; Fraga Rodrigues SM; Broos R; Belkouz A; Meijer LL; Le Large TYS; Erdmann JI; Hooijer GKJ; Heger M; Van Laarhoven HWM; Roos E; Kazemier G; Giovannetti E; Verheij J; Klümpen HJ
    Front Pharmacol; 2023; 14():1274692. PubMed ID: 37920204
    [No Abstract]   [Full Text] [Related]  

  • 44. Identification of laminin γ2 as a prognostic and predictive biomarker for determining response to gemcitabine-based therapy in pancreatic ductal adenocarcinoma.
    Okada Y; Nishiwada S; Yamamura K; Sho M; Baba H; Takayama T; Goel A
    Eur J Cancer; 2021 Mar; 146():125-134. PubMed ID: 33607476
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Gemcitabine versus FOLFIRINOX in patients with advanced pancreatic adenocarcinoma hENT1-positive: everything was not too bad back when everything seemed worse.
    Orlandi A; Calegari MA; Martini M; Cocomazzi A; Bagalà C; Indellicati G; Zurlo V; Basso M; Cassano A; Larocca LM; Barone C
    Clin Transl Oncol; 2016 Oct; 18(10):988-95. PubMed ID: 26742940
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Concurrent analysis of human equilibrative nucleoside transporter 1 and ribonucleotide reductase subunit 1 expression increases predictive value for prognosis in cholangiocarcinoma patients treated with adjuvant gemcitabine-based chemotherapy.
    Sasaki H; Murakami Y; Uemura K; Sudo T; Hashimoto Y; Kondo N; Sueda T
    Br J Cancer; 2014 Sep; 111(7):1275-84. PubMed ID: 25032731
    [TBL] [Abstract][Full Text] [Related]  

  • 47. hENT1 Expression Predicts Response to Gemcitabine and Nab-Paclitaxel in Advanced Pancreatic Ductal Adenocarcinoma.
    Perera S; Jang GH; Wang Y; Kelly D; Allen M; Zhang A; Denroche RE; Dodd A; Ramotar S; Hutchinson S; Tehfe M; Ramjeesingh R; Biagi J; Lam B; Wilson J; Fischer SE; Zogopoulos G; Notta F; Gallinger S; Grant RC; Knox JJ; O'Kane GM
    Clin Cancer Res; 2022 Dec; 28(23):5115-5120. PubMed ID: 36222851
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Human equilibrative nucleoside transporter 1 (hENT1) levels predict response to gemcitabine in patients with biliary tract cancer (BTC).
    Santini D; Schiavon G; Vincenzi B; Cass CE; Vasile E; Manazza AD; Catalano V; Baldi GG; Lai R; Rizzo S; Giacobino A; Chiusa L; Caraglia M; Russo A; Mackey J; Falcone A; Tonini G
    Curr Cancer Drug Targets; 2011 Jan; 11(1):123-9. PubMed ID: 20578980
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Human equilibrative nucleoside transporter 1, as a predictor of 5-fluorouracil resistance in human pancreatic cancer.
    Tsujie M; Nakamori S; Nakahira S; Takahashi Y; Hayashi N; Okami J; Nagano H; Dono K; Umeshita K; Sakon M; Monden M
    Anticancer Res; 2007; 27(4B):2241-9. PubMed ID: 17695509
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Human equilibrative nucleoside transporter 1 expression is a strong independent prognostic factor in UICC T3-T4 pancreatic cancer patients treated with preoperative gemcitabine-based chemoradiotherapy.
    Murata Y; Hamada T; Kishiwada M; Ohsawa I; Mizuno S; Usui M; Sakurai H; Tabata M; Ii N; Inoue H; Shiraishi T; Isaji S
    J Hepatobiliary Pancreat Sci; 2012 Jul; 19(4):413-25. PubMed ID: 21898089
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Transcription analysis of human equilibrative nucleoside transporter-1 predicts survival in pancreas cancer patients treated with gemcitabine.
    Giovannetti E; Del Tacca M; Mey V; Funel N; Nannizzi S; Ricci S; Orlandini C; Boggi U; Campani D; Del Chiaro M; Iannopollo M; Bevilacqua G; Mosca F; Danesi R
    Cancer Res; 2006 Apr; 66(7):3928-35. PubMed ID: 16585222
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Human equilibrative nucleoside transporter 1 (hENT1) protein is associated with short survival in resected ampullary cancer.
    Santini D; Perrone G; Vincenzi B; Lai R; Cass C; Alloni R; Rabitti C; Antinori A; Vecchio F; Morini S; Magistrelli P; Coppola R; Mackey JR; Tonini G
    Ann Oncol; 2008 Apr; 19(4):724-8. PubMed ID: 18187485
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Combined Analyses of hENT1, TS, and DPD Predict Outcomes of Borderline-resectable Pancreatic Cancer.
    Yabushita Y; Mori R; Taniguchi K; Matsuyama R; Kumamoto T; Sakamaki K; Kubota K; Endo I
    Anticancer Res; 2017 May; 37(5):2465-2476. PubMed ID: 28476815
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Progress in pancreatic cancer: moving beyond gemcitabine?
    Basu B; Jodrell D
    Expert Rev Anticancer Ther; 2012 Aug; 12(8):997-1000. PubMed ID: 23030218
    [No Abstract]   [Full Text] [Related]  

  • 55. hENT1's role in adjuvant intra-arterial gemcitabine-based chemotherapy for resectable pancreatic cancer patients.
    Wang W; Yu X; Li H; Yang C; Jin C; Huang X
    BMC Gastroenterol; 2023 Feb; 23(1):35. PubMed ID: 36755224
    [TBL] [Abstract][Full Text] [Related]  

  • 56. The prognostic significance of human equilibrative nucleoside transporter 1 expression in patients with metastatic bladder cancer treated with gemcitabine-cisplatin-based combination chemotherapy.
    Matsumura N; Nakamura Y; Kohjimoto Y; Inagaki T; Nanpo Y; Yasuoka H; Ohashi Y; Hara I
    BJU Int; 2011 Jul; 108(2 Pt 2):E110-6. PubMed ID: 21166756
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Do hENT1 and RRM1 predict the clinical benefit of gemcitabine in pancreatic cancer?
    Jordheim LP; Dumontet C
    Biomark Med; 2013 Aug; 7(4):663-71. PubMed ID: 23905902
    [TBL] [Abstract][Full Text] [Related]  

  • 58. S100A14 promotes progression and gemcitabine resistance in pancreatic cancer.
    Zhu H; Gao W; Li X; Yu L; Luo D; Liu Y; Yu X
    Pancreatology; 2021 Apr; 21(3):589-598. PubMed ID: 33579599
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Prognostic roles of human equilibrative transporter 1 (hENT-1) and ribonucleoside reductase subunit M1 (RRM1) in resected pancreatic cancer.
    Kim R; Tan A; Lai KK; Jiang J; Wang Y; Rybicki LA; Liu X
    Cancer; 2011 Jul; 117(14):3126-34. PubMed ID: 21264835
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Prognostic effect of hENT1, dCK and HuR expression by morphological type in periampullary adenocarcinoma, including pancreatic cancer.
    Elebro J; Ben Dror L; Heby M; Nodin B; Jirström K; Eberhard J
    Acta Oncol; 2016; 55(3):286-96. PubMed ID: 26362587
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.